HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Travere Therapeutics and raised the price target from $20 to $23, indicating confidence in the company's future performance.
September 06, 2024 | 11:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Travere Therapeutics and increased the price target from $20 to $23, suggesting a positive outlook for the company's stock.
The analyst's decision to maintain a Buy rating and raise the price target indicates a strong belief in the company's potential for growth. This is likely to positively influence investor sentiment and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100